Rapid increase in Humira biosimilar orders after CVS formulary change not sustained

Prescriptions for an adalimumab biosimilar among new users rose from 0% to 24% after CVS Caremark added it to its formulary, but then fell to 10% 1 month later, according to data published in Arthritis Care & Research.“Adalimumab is the highest-grossing drug in history, and legal battles delayed the market launch of biosimilar competition by about 6 years,” Eric T. Roberts, PhD,